Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the superior commercial and clinical portfolios of the Indianapolis company ...

The company says its new drug in pill form is as safe and effective as Ozempic and other popular injectables for weight loss ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

Source: FactSet Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. Sources: FactSet ...

Novo Nordisk A/S NVO on Saturday presented the ... in adults with type 2 diabetes and PAD, at the American College of Cardiology’s (ACC) Annual Scientific Session and Expo.

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of ...

Novo Nordisk on Saturday said its diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, paving the way for it to become a new treatment option for people living with ...

March 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is ... for conditions such as obesity and nerve damage caused by diabetes, and was looking for partners to help make advancements ...